AR097881A1 - FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO - Google Patents

FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO

Info

Publication number
AR097881A1
AR097881A1 ARP140103655A ARP140103655A AR097881A1 AR 097881 A1 AR097881 A1 AR 097881A1 AR P140103655 A ARP140103655 A AR P140103655A AR P140103655 A ARP140103655 A AR P140103655A AR 097881 A1 AR097881 A1 AR 097881A1
Authority
AR
Argentina
Prior art keywords
hmpv
need
metapneumovirus
liofilized
lives
Prior art date
Application number
ARP140103655A
Other languages
English (en)
Inventor
Mikes Kalergis Parra Alexis
Marcela Bueno Ramrez Susan
Palavecino Beaumont Christian
Original Assignee
Pontificia Univ Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Univ Católica De Chile filed Critical Pontificia Univ Católica De Chile
Publication of AR097881A1 publication Critical patent/AR097881A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud describe una formulación inmunogénica para ser utilizada en mamíferos contra Metapneumovirus humano (hMPV) consistente en un liofilizado de 1 x 10⁹ ufc/ml de BCG recombinantes que expresa la proteína viral P de hMPV (de los genogrupos A1, A2, B1 y B2). La vacuna esta derivada del producto completo o parcial del gen P de hMPV pudiendo ser utilizadas, estabilizadas y administradas en solución sin la necesidad de adyuvantes. La preparación puede contener además combinaciones de formulaciones descritas anteriormente. La formulación está estabilizada por liofilización (rango de conservación entre 4ºC y 8ºC), para ser posteriormente reconstituida en una solución salina sin adyuvante previo a su uso.
ARP140103655A 2013-10-01 2014-10-01 FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO AR097881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2013002829A CL2013002829A1 (es) 2013-10-01 2013-10-01 Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.

Publications (1)

Publication Number Publication Date
AR097881A1 true AR097881A1 (es) 2016-04-20

Family

ID=52778317

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103655A AR097881A1 (es) 2013-10-01 2014-10-01 FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO

Country Status (17)

Country Link
US (1) US9999663B2 (es)
EP (1) EP3054013B1 (es)
KR (1) KR101822836B1 (es)
CN (1) CN105745323B (es)
AR (1) AR097881A1 (es)
BR (1) BR112016006989B1 (es)
CA (1) CA2925369C (es)
CL (1) CL2013002829A1 (es)
DE (1) DE112014004530T5 (es)
ES (1) ES2853355T3 (es)
GB (1) GB2532699B (es)
MX (1) MX2016003783A (es)
PE (1) PE20160536A1 (es)
RU (1) RU2665848C2 (es)
UY (1) UY35765A (es)
WO (1) WO2015049633A1 (es)
ZA (1) ZA201602148B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2019003847A1 (es) * 2019-12-26 2021-08-06 Univ Pontificia Catolica Chile Nuevo uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
JP2024510532A (ja) * 2020-12-23 2024-03-07 ポンティフィシア・ウニベルシダ・カトリカ・デ・チリ ＣＯＶＩＤ‐１９の発症を予防、治療、又は減弱するのに有用な、ＳＡＲＳ‐ＣｏＶ‐２タンパク質を発現する１つ又は複数の改変ＢＣＧ株を含有する免疫原性製剤
CN114748615A (zh) * 2022-04-29 2022-07-15 成都安永鼎业生物技术有限公司 一种治疗用重组卡介苗的冻干制剂及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1351981T3 (da) * 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US20040005545A1 (en) * 2002-02-21 2004-01-08 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
MXPA05011268A (es) * 2003-04-25 2006-06-20 Medimmune Vaccines Inc Sistemas de expresion de virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metaneumovirus.
US9034343B2 (en) * 2005-01-12 2015-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated human parainfluenza virus, methods and uses thereof
WO2008137981A1 (en) * 2007-05-08 2008-11-13 Us Government As Represented By The Secy Of The Department Of Health And Human Services Human parainfluenza viruses having separated p and c genes
CL2007002710A1 (es) * 2007-09-20 2008-01-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
GB0809881D0 (en) * 2008-05-30 2008-07-09 Genomica Sau Method for detecting respiratory viral agents in a test sample

Also Published As

Publication number Publication date
US20160220662A1 (en) 2016-08-04
PE20160536A1 (es) 2016-06-05
GB201605054D0 (en) 2016-05-11
ES2853355T3 (es) 2021-09-15
UY35765A (es) 2015-04-30
EP3054013B1 (en) 2020-11-11
CN105745323B (zh) 2020-09-04
BR112016006989B1 (pt) 2023-10-17
DE112014004530T5 (de) 2016-10-06
ZA201602148B (en) 2017-06-28
WO2015049633A1 (es) 2015-04-09
CN105745323A (zh) 2016-07-06
MX2016003783A (es) 2017-01-20
GB2532699A (en) 2016-05-25
EP3054013A1 (en) 2016-08-10
GB2532699B (en) 2020-05-13
BR112016006989A2 (pt) 2017-09-19
KR20160058185A (ko) 2016-05-24
EP3054013A4 (en) 2016-08-31
KR101822836B1 (ko) 2018-01-29
CA2925369C (en) 2020-09-22
US9999663B2 (en) 2018-06-19
RU2665848C2 (ru) 2018-09-04
RU2016111978A (ru) 2017-11-10
CL2013002829A1 (es) 2014-04-04
CA2925369A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
PH12018502403A1 (en) Hiv vaccine formulation
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
BR112013009649A2 (pt) composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
MX2015004290A (es) Formulacion que contiene virus y uso de la misma.
BRPI0905725B8 (pt) vacina e embalagem farmacêutica
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
JP2012021028A5 (es)
AR097881A1 (es) FORMULACIÓN INMUNOGÉNICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTÍGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSIÓN QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE ADYUVANTE, APTA PARA SU USO FARMACÉUTICO
WO2013104995A3 (en) Compositions and methods for treating viral infections
WO2015095167A3 (en) Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
BR112016025977A2 (pt) composições, métodos e utilizações para formulações de papilomavirus humano estábulo estável
JP2016534062A5 (es)
BR112018017173A2 (pt) composições e métodos para a produção e uso de formulações imunogênicas termoestáveis com compatibilidade aumentada de uso como vacinas contra um ou mais patógenos
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
WO2014165829A3 (en) Nanoparticle formulations
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
MX2017000154A (es) Sistema de rinovacunacion de la vacuna contra la influenza.
AR120887A1 (es) Uso de formulación inmunogénica bcg que expresa una proteína de virus respiratorio sincicial contra hmpv
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
CO6690780A2 (es) Formulaciones para el factor estimulante de colonias de granulocitos bovino y variantes de las mismas